• Story Reviews
  • News Release Reviews
  • Blog
  • Podcasts
  • About Us
  • Toolkit for journalists and consumers
  • Contact
  • Newsletter Signup
HealthNewsReview.org HealthNewsReview.org HealthNewsReview.org
  • 2616 Story Reviews
  • 606 News Release Reviews
  • 2946 Blog Posts
  • Home
  • Story Reviews
  • News Release Reviews
  • Blog
  • Podcasts
  • About Us
    • Editorial Team
    • What We Review and How
    • Review Criteria
    • How Is the Star Score Determined?
    • Our Comments Policy
    • Accolades for HealthNewsReview.org
    • Talks, Workshops & Presentations
  • Toolkit
    • Tips for Analyzing Studies & Health Care Claims
    • Just for Journalists: Writing Tips
    • Stories of Patient Harm from Misleading Media
    • Pre-publication News Release Review
    • Health News Watchdog podcasts
    • News Sites & Blogs We Like
    • List of Industry-Independent Experts
    • Links to Other Resources
  • Contact

Search Results for "off-label"

8 8/24/2012

Robotic thyroid surgery doubles the expense

To a man with a new hammer, everything looks like a nail. To a hospital and/or surgical team with a new robotic surgery system, everything looks like a prime candidate for the robot. And then there’s this about “off-label” use of the robot for thyroid surgery: Reuters Health reports: “Surgery to remove part of the […]

8/15/2012

Guest post followup: Why does National Library of Medicine still index Reviews in Cardiovascular Medicine?

The following is a guest post by Kevin Lomangino, one of our story reviewers on HealthNewsReview.org. He is an independent medical journalist and editor who is currently Editor-in-Chief of Clinical Nutrition Insight, a monthly evidence-based newsletter which reviews the scientific literature on nutrition for physicians and dietitians. He tweets as @Klomangino. ———————————————————————————— Why Is the […]

8/8/2012

Disclosing conflict of interest: two pieces in TheScientist.com

Both worth a closer look: An opinion piece on TheScientist.com, “Bias Is Unavoidable:  Simply disclosing conflicts of interest is not enough.” and An opinion piece, “Off-Label Drug Disclosure Inadequate:  Some 85 percent of researchers involved in promoting off-label drug use do not adequately disclose financial conflicts of interest in published articles.”

July 18, 2012 | Story Review 1

Immune-Disorder Drug Shows Promise for Alzheimer’s

There were many strong elements in this story:  cautious language early and often, strong input from independent experts, and concerns stated about off-label use.  Nice job.

4 Star
The Wall Street Journal

Immune-Disorder Drug Shows Promise for Alzheimer’s

6/21/2012

USA Today piece on pain patches gives hospitalist a headache

Dr. Bradley Flansbaum, who blogs on The Hospitalist Leader, is Director of Hospitalist Services at Lenox Hill Hospital in New York City.  He’s also a keen observer of health care news coverage.  He wrote the following guest post. He wrote to me, saying, “I treat a lot of pain, and always approach any claims re: […]

2/1/2012

Readers may be snared in heart journal’s tangled web of conflicts

The following is a guest post by Kevin Lomangino, one of our story reviewers on HealthNewsReview.org. He is an independent medical journalist and editor who is currently Editor-in-Chief of Clinical Nutrition Insight, a monthly evidence-based newsletter which reviews the scientific literature on nutrition for physicians and dietitians. He tweets as @Klomangino. ———————————————————————————————- Blogger Marilyn Mann […]

12/6/2011

Don’t miss our Toolkit – to help journalists & consumers

As one clear sign of how we want to help improve the flow of health care information – not just criticize things we see that are communicated inadequately – we’ve built a section of the site called The Toolkit.  We plan to continue to add to the Toolkit as time permits and we welcome your […]

6
Evaluating claims about medical research
10/7/2011

Tips for analyzing studies, medical evidence and health care claims

To back up our goal of improving the public dialogue about health care interventions, we offer these tips for analyzing studies and health care claims and interventions, aimed at helping both journalists and consumers. We also offer writing tips for health care journalists that touch upon some of these issues. Absolute vs. relative risk Animal […]

8/10/2011

Laurel & Hardy and prostate cancer chemoprevention

In the sometimes Laurel-and-Hardy-like (“Here’s another fine mess you’ve gotten us into!”) interactions between industry, government, and clinicians, there’s a debate brewing about whether drugs used to treat benign prostate problems (BPH) should also be used to try to prevent cancer of the prostate. (Photo credit: http://www.flickr.com/photos/karlosofsyston/) The drugs are of the class called 5-alpha […]

7/15/2011

Reminder of our online toolkit: tips for understanding studies

Many visitors to this site may still be unaware of one important little corner of the site – our “Tips for Understanding Studies.” It’s just a collection of brief little primers on important topics such as: Resources for Reporting on Costs of Medical Interventions Association Versus Causation (primer on limitations of observational studies) “Off-label” Drug […]

6/28/2011

“Harm has been done” – spine journal’s critical review of Medtronic Infuse studies

The Spine Journal has published a special June issue focusing on Medtronic’s INFUSE product, or rhBMP-2, a bone growth product commonly used in spine fusion surgeries. A journal news release states: A critical review of 13 industry-sponsored studies on a spine surgery product found that the actual risk of adverse events was 10 to 50 […]

6 11/4/2010

Drug company's secret inducements to get docs to use $2,000 drug instead of $20 sibling

The New York Times reports: Genentech has begun offering secret rebates to eye doctors as an apparent inducement to get them to use more of the company’s expensive drug Lucentis rather than a less costly alternative. Under the program, which started on Oct. 1, medical practices can earn up to tens of thousands of dollars […]

5/6/2010

A day in the life of misleading drug promotions by pharma

These were all in the news yesterday. • FDA warns Novartis about two websites that the FDA says “are concerning from a public health perspective because they promote Gleevec for an unapproved use, fail to disclose the risks associated with the use of Gleevec, and make unsubstantiated dosing claims about this medication that can put […]

8/4/2009

A growing public health threat: network TV morning health news segments

By reviewing health news coverage every day, we are able to see big pictures of clear patterns unfolding that the casual day-to-day news consumer may miss. One picture is quite clear. The morning health news segments on ABC, CBS and NBC do the following regularly: • Unquestioningly promote new drugs and new technologies • Feed […]

8/3/2009

Network TV morning health news segments may be harmful to your health

By reviewing health news coverage every day, we are able to see big pictures of clear patterns unfolding that the casual day-to-day news consumer may miss. One picture is quite clear.  The morning health news segments on ABC, CBS and NBC do the following regularly: Unquestioningly promote new drugs and new technologies Feed the “worried […]

  • « Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next »

Toolkit

Tips & Resources for Analyzing Health Care Claims

Surrogate markers may not tell the whole story

Screening: How overdiagnosis and other harms can undermine the benefits

A place to tell stories of patient harm from misleading media

View More

Toolkit

Institutional Home

University of Minnesota - School of Public Health
  • Home
  • Story Reviews
  • News Release Reviews
  • Blog
  • About Us
  • Toolkit
  • Contact

Copyright © 2022 HealthNewsReview.org